The ELEVATE Study shows that atogepant effectively prevents episodic migraine.

Published Date: 24 Apr 2023

Atogepant (Qulipta) performed better than a placebo in the ELEVATE study for preventing episodic migraine in patients who were resistant to other treatments.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

An "exploding" field of antibody-drug conjugates is making progress against ovarian cancer.

2.

Telehealth in the pandemic era resulted in fewer therapy interruptions.

3.

Clinical trial is testing whether heavy lifting could combat cancer side effects

4.

In high-risk muscle invasive urothelial cancer, adjuvant pembrolizumab improves disease-free survival.

5.

Rural colon cancer patients face higher risks, but minimally invasive surgery could narrow gap


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot